Tough end to 2024 Market to turn positive in '25e, according to report Re-setting expectation, '25e ...
Redeye comments on Neola Medical’s approved clinical study in Sweden, which is expected to run for a...
Tessin tillhandahåller en digital investeringsplattform för säkerställda fastighetslån.
Stronger end to Q4 vs the PW in Dec Adj. EBITA 18% higher than guided for Estimates up slightly toda...
Adj. EBIT +85% vs ABGSCe Soft cash flow generation Estimates likely up 10% on adj.
Redeye comments on the Q4 report from Moberg Pharma.
Net sales SEK 537m, +3% vs ABGSCe, 0% vs Factset cons.
Redeye will likely retain its view of Hanza following a Q4 report with sales and EBITA slightly belo...
In our view, earnings will become more stable, as the company seems satisfied with its structure aft...
Revenue growth could be as high as ~50% y/y for Q4 2024E, due to a low comparison.
Q4e soft, market remains muted Lower range of targets likely Recovery postponed, '25 also slow Q4e ...
Solteq reports Q4’24 results on Thursday, February 13th.
Redeye gives a short comment on the news that Saniona’s partner Medix will file a final version of T...
After the recent rights issue, Ascelia has SEK 75.
Redeye takes a positive stance on Teneo AI raising SEK60m from a directed share issue.
We expect two more quarters before a return to growth '25e-'26e EBIT down 19-7%; 26% CAGR '24-'27e 2...
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Redeye updates on EG7 post Q4-results which were in line with our forecast.
Redeye makes positive estimate adjustments on the back of I-Tech’s record Q4 report delivering y/y g...
Redeye state Gapwaves delivered a strong report with Net sales and EBITDA excl.